Propanc Biopharma issues 3.5 million restricted shares to executives, directors, service providers
PPCB•Board approves restricted share issuances
Propanc Biopharma board resolutions dated July 24, 2026 were executed via majority shareholder written consent.
The company authorized the issuance of 3.5 million restricted common shares to officers, directors, and service providers under NASDAQ Listing Rules 5635(b) and 5635(c).
The largest allocation is 1 million restricted shares to CEO James Nathanielsz, while multiple other recipients are slated for 250,000 shares each.
The action becomes effective 20 days after the information statement is first mailed, scheduled on or about Aug. 20, 2026.
